These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 32282634)
1. The use of multiparametric 18F-fluoro-L-3,4-dihydroxy-phenylalanine PET/MRI in post-therapy assessment of patients with gliomas. Fraioli F; Shankar A; Hyare H; Ferrazzoli V; Militano V; Samandouras G; Mankad K; Solda F; Zaccagna F; Mehdi E; Lyasheva M; Bomanji J; Novruzov F Nucl Med Commun; 2020 Jun; 41(6):517-525. PubMed ID: 32282634 [TBL] [Abstract][Full Text] [Related]
2. Multiparametric Analysis Combining DSC-MR Perfusion and [18F]FET-PET is Superior to a Single Parameter Approach for Differentiation of Progressive Glioma from Radiation Necrosis. Panholzer J; Malsiner-Walli G; Grün B; Kalev O; Sonnberger M; Pichler R Clin Neuroradiol; 2024 Jun; 34(2):351-360. PubMed ID: 38157019 [TBL] [Abstract][Full Text] [Related]
3. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Pafundi DH; Laack NN; Youland RS; Parney IF; Lowe VJ; Giannini C; Kemp BJ; Grams MP; Morris JM; Hoover JM; Hu LS; Sarkaria JN; Brinkmann DH Neuro Oncol; 2013 Aug; 15(8):1058-67. PubMed ID: 23460322 [TBL] [Abstract][Full Text] [Related]
4. Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas. Youland RS; Pafundi DH; Brinkmann DH; Lowe VJ; Morris JM; Kemp BJ; Hunt CH; Giannini C; Parney IF; Laack NN J Neurooncol; 2018 May; 137(3):583-591. PubMed ID: 29330751 [TBL] [Abstract][Full Text] [Related]
5. Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI. Cicone F; Filss CP; Minniti G; Rossi-Espagnet C; Papa A; Scaringi C; Galldiks N; Bozzao A; Shah NJ; Scopinaro F; Langen KJ Eur J Nucl Med Mol Imaging; 2015 May; 42(6):905-15. PubMed ID: 25750084 [TBL] [Abstract][Full Text] [Related]
16. 11C-CHO PET in optimization of target volume delineation and treatment regimens in postoperative radiotherapy for brain gliomas. Li FM; Nie Q; Wang RM; Chang SM; Zhao WR; Zhu Q; Liang YK; Yang P; Zhang J; Jia HW; Fang HH Nucl Med Biol; 2012 Apr; 39(3):437-42. PubMed ID: 22172386 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. Rapp M; Heinzel A; Galldiks N; Stoffels G; Felsberg J; Ewelt C; Sabel M; Steiger HJ; Reifenberger G; Beez T; Coenen HH; Floeth FW; Langen KJ J Nucl Med; 2013 Feb; 54(2):229-35. PubMed ID: 23232275 [TBL] [Abstract][Full Text] [Related]
19. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. Kim YH; Oh SW; Lim YJ; Park CK; Lee SH; Kang KW; Jung HW; Chang KH Clin Neurol Neurosurg; 2010 Nov; 112(9):758-65. PubMed ID: 20619531 [TBL] [Abstract][Full Text] [Related]
20. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas? Weber MA; Henze M; Tüttenberg J; Stieltjes B; Meissner M; Zimmer F; Burkholder I; Kroll A; Combs SE; Vogt-Schaden M; Giesel FL; Zoubaa S; Haberkorn U; Kauczor HU; Essig M Invest Radiol; 2010 Dec; 45(12):755-68. PubMed ID: 20829706 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]